What do systematic reviews say?

Sucralfate vs placebo

Summary of findings: Sucralfate showed no clear difference in acute and late GI toxicity (grade 2+) [acute = during RT; late = 6… compared with placebo (moderate certainty).

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  RR 1.07 [0.83, 1.39]
  1 study · 335 participants
  Moderate

Sucralfate vs placebo

Summary of findings: Sucralfate may leads to lower diarrhoea (grade 2+) [during RT] compared with placebo (low certainty).

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  RR 0.81
  4 studies · 284 participants
  Low

Sucralfate vs placebo

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Octreotide vs placebo

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Octreotide vs placebo

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Octreotide vs placebo

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Octreotide vs placebo

Summary of findings: Octreotide showed no clear difference in diarrhoea (grade 2+) compared with placebo (moderate certainty).

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  RR 1.01 [0.76, 1.35]
  2 studies · 340 participants
  Moderate

Summary of findings: Octreotide vs placebo

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Misoprostol vs placebo

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Misoprostol vs placebo

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Misoprostol vs placebo

Summary of findings: Misoprostol showed no clear difference in acute and late GI toxicity (grade 2+) compared with placebo (low certainty).

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  RR 1.38 [0.76, 2.51]
  1 study · 100 participants
  Low

Misoprostol vs placebo

It is very uncertain whether summary of findings: Misoprostol changes diarrhoea (grade 2+) compared with placebo (very low certainty).

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  RR 1 [0.46, 2.19]
  1 study · 100 participants
  Very low

Misoprostol vs placebo

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Conformal RT vs conventional dose RT

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  0 participants
  GRADE not reported

Summary of findings: Conformal RT vs conventional dose RT

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 307 participants
  High

Summary of findings: Conformal RT vs conventional dose RT

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  0 participants
  GRADE not reported

Summary of findings: Conformal RT vs conventional dose RT

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  0 participants
  GRADE not reported

Imiquimod vs placebo

Summary of findings for imiquimod leads to higher response to treatment at 5 to 6 months ‐ overall response compared with placebo (high certainty).

• Medical and surgical interventions for the treatment of usual‐type vulval intraepithelial neoplasia 2016 · Cochrane Headline outcomes only
  RR 11.95 [3.21, 44.51]
  3 studies · 104 participants
  High

Imiquimod vs cidofovir

Summary of findings for imiquimod showed no clear difference in response to treatment at 6 months ‐ complete response compared with cidofovir (moderate certainty).

• Medical and surgical interventions for the treatment of usual‐type vulval intraepithelial neoplasia 2016 · Cochrane Headline outcomes only
  RR 1 [0.73, 1.37]
  1 study · 180 participants
  Moderate

Imiquimod vs cidofovir

Summary of findings for imiquimod showed no clear difference in pain ‐ any grade compared with cidofovir (moderate certainty).

• Medical and surgical interventions for the treatment of usual‐type vulval intraepithelial neoplasia 2016 · Cochrane Headline outcomes only
  RR 1.16 [0.92, 1.47]
  1 study · 168 participants
  Moderate